FBT
TEVA icon

First Bankers Trust’s Teva Pharmaceuticals TEVA Stock Holding History

First Bankers Trust’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-6,765
Closed -$225K – 125
2017
Q2 		$225K Sell
6,765
-100
-1% -$3.1K 0.12% 119
2017
Q1 		$220K Sell
6,865
-100
-1% -$3.41K 0.12% 119
2016
Q4 		$252K Hold
6,965
– – 0.14% 113
2016
Q3 		$320K Buy
+6,965
New +$363K 0.18% 101

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

First Bankers Trust's TEVA Position: Q3 2017 in Review

First Bankers Trust sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 6,765 shares — an estimated $225K sold.

First Bankers Trust first reported a position in TEVA in Q3 2016 and held it in 4 quarters. The position peaked at $320K in Q3 2016. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • First Bankers Trust reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • First Bankers Trust sold 6,765 Teva Pharmaceuticals shares in Q3 2017, an estimated $225K.
  • First Bankers Trust first reported a position in Teva Pharmaceuticals in Q3 2016 and held it in 4 quarters.
  • First Bankers Trust's Teva Pharmaceuticals position peaked at $320K in Q3 2016.
  • 535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on First Bankers Trust's 13F filing for Q3 2017, filed 19 Oct 2017.